Sleep Disorders

Treatment is now the first and only once-at-bedtime oxybate to be approved by the FDA for individuals with narcolepsy.

Let's discuss the importance of a sleep conducive environment.

Sleep experts present a case of an 18-year-old female preparing for college with EDS and cataplexy, and share their approach to treatment.

Drs Asim Roy and Richard K. Bogan discuss remaining unmet needs in the therapeutic landscape for narcolepsy.

Richard K. Bogan, MD, FCCP, FAASM, and Asim Roy, MD, comment on the evolving treatment landscape for narcolepsy and patient selection of FDA-approved agents: solriamfetol, pitolisant, and lower-sodium oxybate.

Experts in sleep medicine share insight on initiating treatment for the management of narcolepsy.

Sleep experts comment on diagnostic criteria for narcolepsy, factors that may lead to misdiagnosis, and the impact of the condition on a patient’s quality of life.

Richard K. Bogan, MD, FCCP, FAASM, and Asim Roy, MD, provide an overview of the pathophysiology of narcolepsy and the role of orexin in regulating the sleep/wakefulness cycle.

Researchers investigated sleep disturbances in individuals at ultra-high risk of psychosis.

The value of a good night's sleep...

Sleep and suicide: researchers performed a systematic review and meta-analysis of objective sleep markers of suicidal behaviors in patients with psychiatric disorders.

Sleep disturbances can exacerbate TBI symptoms. Here’s how to address them.

Many individuals do not get medical support for insomnia. Here's how you can help.

Cognitive and psychiatric symptoms at 3 months post-stroke might predict daytime sleepiness and fatigue at 12 months.

Survey results shed light on the effects of insomnia and obstacles to effective treatment.

Drs Paul Doghramji and Leslie Citrome share approaches to communicate with patients and increase awareness of insomnia disorder

Experts discuss daridorexant efficacy and safety data, and dosing considerations and what to communicate with patients when using daridorexant for insomnia.

Drs Paul Doghramji and Leslie Citrome provide an overview of dual orexin receptor antagonists (DORAs), suvorexant, lemborexant, and daridorexant, in treatment of insomnia disorder.

New research explores the impact of GAT on TGNC youth.

Drs Paul Doghramji and Leslie Citrome discuss the sleep and wakefulness signals and pathways that contribute to insomnia.

Drs Paul Doghramji and Leslie Citrome review the use of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) to assess treatment efficacy.

Experts discuss treatment for patients experiencing insomnia in conjunction with other health conditions.

Drs Paul Doghramji and Leslie Citrome review prescription drugs and over-the-counter remedies for treating insomnia.

Experts highlight cognitive behavioral therapy for insomnia (CBTI) and sleep hygiene as nonpharmacological approaches to the treatment of insomnia.

Drs Paul Doghramji and Leslie Citrome discuss daytime sleepiness and other symptoms of insomnia and their impact on quality of life.

Experts review the co-occurrence of insomnia with other medical conditions and discuss risks and triggers that lead to insomnia, such as age and psychiatric conditions.

Drs Paul Doghramji and Leslie Citrome provide an overview of the diagnosis and prevalence of insomnia.

Connections between autism risk, sleep disturbances, insomnia risk genes and circadian pathways were analyzed.

From herbal medicine for psychiatrists to the psychiatric implications of the Parkland School massing shooting, here are highlights from the week in Psychiatric Times.

Does the YOI intervention improve mental health workers’ insomnia? Research says yes.